PTEIQ vs. SONN, PLRZ, UPXI, LIPO, ATNF, ALLR, SNPX, SNOA, CPHI, and ARTL
Should you be buying PolarityTE stock or one of its competitors? The main competitors of PolarityTE include Sonnet BioTherapeutics (SONN), Polyrizon (PLRZ), Upexi (UPXI), Lipella Pharmaceuticals (LIPO), 180 Life Sciences (ATNF), Allarity Therapeutics (ALLR), Synaptogenix (SNPX), Sonoma Pharmaceuticals (SNOA), China Pharma (CPHI), and Artelo Biosciences (ARTL). These companies are all part of the "pharmaceutical products" industry.
PolarityTE vs.
PolarityTE (NASDAQ:PTEIQ) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and community ranking.
PolarityTE's return on equity of -106.08% beat Sonnet BioTherapeutics' return on equity.
Sonnet BioTherapeutics has lower revenue, but higher earnings than PolarityTE.
11.8% of PolarityTE shares are owned by institutional investors. Comparatively, 9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. 5.4% of PolarityTE shares are owned by insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Sonnet BioTherapeutics received 20 more outperform votes than PolarityTE when rated by MarketBeat users.
PolarityTE has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Sonnet BioTherapeutics has a consensus target price of $20.00, suggesting a potential upside of 1,288.89%. Given Sonnet BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sonnet BioTherapeutics is more favorable than PolarityTE.
In the previous week, Sonnet BioTherapeutics had 3 more articles in the media than PolarityTE. MarketBeat recorded 3 mentions for Sonnet BioTherapeutics and 0 mentions for PolarityTE. PolarityTE's average media sentiment score of 0.00 equaled Sonnet BioTherapeutics'average media sentiment score.
Summary
Sonnet BioTherapeutics beats PolarityTE on 7 of the 13 factors compared between the two stocks.
Get PolarityTE News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTEIQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTEIQ vs. The Competition
PolarityTE Competitors List
Related Companies and Tools
This page (NASDAQ:PTEIQ) was last updated on 2/22/2025 by MarketBeat.com Staff
Free PTEIQ Stock Alerts